EpiCom
15June2023

Introduction of new EpiCom Committee Members for 2023

Julien Kirchgesner, EpiCom Chair

Julien Kirchgesner
© ECCO

During the recent ECCO Congress in Copenhagen, EpiCom said goodbye to Valérie Pittet and Behrooz Z. Alizadeh while Kristine Allin and Iago Rodríguez-Lago were welcomed as new Committee Members. We thank Valérie and Behrooz for their dedication to ECCO and wish them huge success in their future academic activities.

Posted in ECCO News, Committee News, EpiCom, Volume 18, Issue 2

27April2023

Best epidemiological abstracts at ECCO’23

Ravi Misra, EpiCom Member


Ravi Misra
© ECCO

A total of 74 epidemiological abstracts and 18 digital oral presentations were presented at ECCO'23 in Copenhagen. Five abstracts of particular interest are discussed below.

A novel population-based UK study by Cooney and colleagues (OP 28) examined the association of IBD and various mental health disorders such as depression, anxiety and self-harm in children and adolescents. A large primary care database was used to identify cases. Each case was propensity matched with four controls. Relative risk of all outcomes up to 10 years in the IBD cohort versus controls was estimated using adjusted Cox proportional hazards models controlling for age, sex, socioeconomic status, ethnicity and other conditions. A total of 3898 young patients with incident IBD were matched to 15,571 controls. IBD patients were significantly more likely to develop PTSD [adjusted hazard ratio (aHR) 2.47, 95% CI 1.23–4.94], eating disorders (aHR 1.85, 95% CI 1.05–3.26), self-harm (aHR 1.49, 95% CI 1.00–2.21), sleep disturbance (aHR 1.40, 95% CI 1.15–1.71), depression (aHR 1.34, 95% CI 1.16–1.56) and anxiety disorder (aHR 1.25, 95% CI 1.06–1.48). These findings highlight the need to screen for these conditions in young patients.

Posted in ECCO News, Committee News, ECCO'23, EpiCom, Volume 18, Issue 1

27April2023

Best epidemiological abstracts at ECCO’23 (Copy)

Ravi Misra, EpiCom Member


Ravi Misra
© ECCO

A total of 74 epidemiological abstracts and 18 digital oral presentations were presented at ECCO'23 in Copenhagen. Five abstracts of particular interest are discussed below.

A novel population-based UK study by Cooney and colleagues (OP 28) examined the association of IBD and various mental health disorders such as depression, anxiety and self-harm in children and adolescents. A large primary care database was used to identify cases. Each case was propensity matched with four controls. Relative risk of all outcomes up to 10 years in the IBD cohort versus controls was estimated using adjusted Cox proportional hazards models controlling for age, sex, socioeconomic status, ethnicity and other conditions. A total of 3898 young patients with incident IBD were matched to 15,571 controls. IBD patients were significantly more likely to develop PTSD [adjusted hazard ratio (aHR) 2.47, 95% CI 1.23–4.94], eating disorders (aHR 1.85, 95% CI 1.05–3.26), self-harm (aHR 1.49, 95% CI 1.00–2.21), sleep disturbance (aHR 1.40, 95% CI 1.15–1.71), depression (aHR 1.34, 95% CI 1.16–1.56) and anxiety disorder (aHR 1.25, 95% CI 1.06–1.48). These findings highlight the need to screen for these conditions in young patients.

Posted in ECCO News, Committee News, ECCO'23, EpiCom, Volume 18, Issue 1

13October2022

New EpiCom member

Valerie Pittet, EpiCom Chair


Valerie Pittet 
© ECCO

As you probably know ECCO Members have to step down and new members take their place - that means fresh ideas and various perspectives are heard, leading to renewed enthusiasm that will drive the EpiCom agenda for the future. The Epidemiological Committee  would like to welcome Ravi Misra as board member, while saying good bye to former Chair Naila Arebi.

Posted in ECCO News, Committee News, EpiCom, Volume 17, Issue 3

15June2022

Genetics of IBD: the most relevant Genetics abstracts at ECCO’22

Behrooz Z. Alizadeh, EpiCom Member


Behrooz Z. Alizadeh
© ECCO

A total of ten abstracts focusing on IBD genetics were accepted for presentation at the 17th Congress of ECCO. Four abstracts were presented in the scientific programme (OP) and two in digital oral presentation (DOP) sessions. The remaining four abstracts were presented as posters (eP). I describe here the most interesting findings from different domains of genetics in IBD.

Posted in ECCO News, Committee News, EpiCom, ECCO'22, Volume 17, Issue 2

15June2022

Epidemiology of IBD: the most relevant epidemiological abstracts at ECCO’22

Behrooz Z. Alizadeh, EpiCom Member


Behrooz Z. Alizadeh
© ECCO

A total of 72 abstracts focusing on IBD epidemiology were accepted for presentation at the 17th Congress of ECCO. Among the best abstracts, seven were presented in digital oral presentation (DOP) sessions. The remaining 65 abstracts were presented as posters. Below, I summarise the most interesting studies, covering various fields in the epidemiology of IBD.

Posted in ECCO News, Committee News, EpiCom, ECCO'22, Volume 17, Issue 2

28April2022

6th EpiCom Workshop: Overview of prognostic factors and outcomes in IBD

Ravi Misra, EpiCom Member

Ravi Misra
© Ravi Misra

The Epidemiological Committee (EpiCom) organised the 6th EpiCom Workshop at the ECCO’22 Virtual Congress. The delegates were welcomed by EpiCom chair, Naila Arebi.

The opening presentation was a tandem talk by Naila Arebi and Valérie Pittet on core outcomes relevant to prognostic factors. The two different types of prognostic study, natural history and clinical course, were described, with identification of their strengths and weaknesses. Emphasis was placed on the importance of these studies in paving the way for personalised medicine by identifying high-risk groups and tailoring treatment accordingly. However, a significant limitation is the heterogeneity of outcomes, which limits comparison. Indeed, over 200 different outcomes have been described for Crohn’s Disease (CD) alone.

Posted in ECCO News, Committee News, EpiCom, ECCO'22, Volume 17, Issue 1

16December2021

A core outcome set for real-world evidence – the dawn of a new era for real-world studies

Naila Arebi, EpiCom Chair

Naila Arebi 
© ECCO

The level of confidence in evidence generated by research is reflected in various aspects of study design and underpins clinical guidelines in Inflammatory Bowel Disease (IBD). The quality of research study designs, each with inherent strengths and limitations, determines confidence in the results, and it is acknowledged that some ‘robust’ study designs may not be feasible in specific contexts [1, 2]. Experimental designs such as randomised controlled studies that are characterised by methodological rigour, may be unsuitable to study effectiveness owing to their weak external validity, which is attributable to their strict eligibility criteria. Reliance on complementary or alternative evidence from other study designs to address residual gaps in knowledge is not uncommon. Non-experimental observational study designs capture a more diverse population, albeit in a less stringent setting, resulting in several methodological limitations, including high risk of bias and unbalanced confounders [2]. The increasing digitalisation of medicine, in addition to accessible diverse sources of data, is partly responsible for recent intensification of interest in evidence generated by analysing data from observational studies with the purpose of offering new insights into the effectiveness and safety of interventions as well as understanding healthcare delivery and quality of care. The systematic analysis of data from multiple data sources outside a research setting is referred to as real-world studies (RWS), and its subsequent analysis and conclusions as real-world evidence (RWE) [3].

Posted in ECCO News, Committee News, EpiCom, Volume 16, Issue 4

17September2021

Best epidemiological abstracts at ECCO’21

Valerie Pittet & Julien Kirchgesner, EpiCom Members

Valerie Pittet
© ECCO


Julien Kirchgesner
© ECCO

A total of 76 abstracts focussing on IBD epidemiology were accepted for presentation at the 16th Congress of ECCO. Among the ten best abstracts, one was presented in the scientific programme and nine in digital oral presentation (DOP) sessions. The remaining 66 abstracts were presented as posters.

Posted in ECCO News, Committee News, EpiCom, ECCO'21, Volume 16, Issue 3

29April2021

Personalised medicine in IBD

Behrooz Alizadeh, EpiCom Member

Behrooz Alizadeh 
© ECCO

Inflammatory Bowel Disease (IBD) is a chronic relapsing and remitting disease of the gut. IBD has a lifelong adverse impact on quality of life and imposes a significant burden on health care [1, 2]. The pathogenesis and course of IBD involve pathogenomic crosstalk among several complex internal components [3, 4], namely the genome [5], epigenome [3, 4], metabolome [3, 4, 6], immunome and microbiome [6–9]; this crosstalk is generally triggered through a set of external complex interactions among the exposome [10–13], dietome [14, 15], lifestyle, social and behavioural factors [16]. While some of these multi-level interactions trigger the disease, others drive the disease course. Therefore, in each IBD patient the disease arises through a (unique) combination of pathogenenomic (risk) factors or pathway that yield a specific set of disease manifestations and a specific disease course. In this context, an “individualized” therapy is required [17–19].

Posted in ECCO News, Committee News, EpiCom, Volume 16, Issue 2